Format

Send to

Choose Destination
J Pharm Biomed Anal. 2017 Oct 25;145:423-430. doi: 10.1016/j.jpba.2017.04.005. Epub 2017 Apr 14.

Development and validation of sensitive LC-MS/MS method for the quantification of SUVN-502 and its metabolite and its application for first in human pharmacokinetic study.

Author information

1
Biopharmaceutical Research, Suven Life Sciences Ltd., Serene Chambers, Road - 5, Avenue - 7, Banjara Hills, Hyderabad 500034, India. Electronic address: ramakrishna_nirogi@yahoo.co.in.
2
Biopharmaceutical Research, Suven Life Sciences Ltd., Serene Chambers, Road - 5, Avenue - 7, Banjara Hills, Hyderabad 500034, India.

Abstract

A sensitive and rapid LC-MS/MS method was developed and validated for the quantification of SUVN-502 and M1 of SUVN-502, a 5-HT6 receptor antagonist for the treatment of dementia associated with Alzheimer's disease. Following solid-phase extraction, SUVN-502 and M1 of SUVN-502 and IS were eluted with 10mM ammonium acetate (pH 4.0) and acetonitrile using a rapid gradient program on reverse phase column. Multiple reaction monitoring mode was used to monitor the respective transitions of m/z 478.2→377.7 for SUVN-502 and m/z 464.1→377.7 for M1 of SUVN-502. The assay exhibited a linear dynamic range of 10-10000pg/mL for SUVN-502 and 20-20000pg/mL for M1 of SUVN-502 in human plasma. Acceptable precision and accuracy were obtained for concentrations over the standard curve range. The within batch accuracy and precision were within acceptable limits. All the other validation parameters were within the acceptable limits. The validated method was applied to analyze human plasma samples obtained from a human pharmacokinetic study consisting single and multiple ascending doses.

KEYWORDS:

5-HT(6) receptor; Alzheimer’s; Dementia; LC–MS/MS; Neurodegeneration; SUVN-502

PMID:
28734271
DOI:
10.1016/j.jpba.2017.04.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center